CROMSOURCE Further Expands Polish Operations
CROMSOURCE
, an international full service contract research organization (CRO) today announced the completion and opening of a new office building in Warsaw, Poland and the movement of key company services to this location.
‘Poland has been a key location for CROMSOURCE since our inception in 1994 ', noted Oriana Zerbini MD, Chief Executive Officer of CROMSOURCE. ‘We have a very large team in Poland which is a key country for delivery of our clinical projects. Our unique expertise in Poland and other Central and Eastern European countries provides our sponsors with the opportunity to complete their projects in a high quality, cost competitive and high enrolling environment. This is in large part due to the wide network of expert and committed investigators with whom CROMSOURCE has established a strong relationship based on mutual trust. I am delighted to announce that our long term project to continually develop our presence in Poland continues with the completed construction of our new offices in Warsaw and the relocation of our general company services there.’
Wanda Malkowska, Managing Director of CROMSOURCE sp. z o.o stated ‘In 2011 we rejected options to lease new premises and instead initiated a plan to invest in the construction of a new office building in Warsaw to accommodate our growing team in Poland. This project, which was entirely self-financed, has now been completed successfully and I can report that the move proceeded without any adverse impact on our operations or service to our clients.’
The new office is located in the Żoliborz district of Warsaw, only 4km (2.5 miles) from the city center and just 12km (7.5 miles) from Chopin airport. The office space is greater than 1000m2 (10,750 ft2) and incorporates a secure basement for archiving and storage. The building will house functions including Clinical Operations, Staffing Solutions, Human Resources Recrutiment & Selection, Accounting, Finance. This is also the location of Financial Service Center Unit that manages all invoicing, accounting and project administration activities for all Group entities following standardised procedures developed over many years.
About CROMSOURCE: CROMSOURCE is a high quality ISO-certified international provider of outsourced services to the pharmaceutical, biotechnology and medical device industries, specialized in clinical development and staffing solutions. CROMSOURCE was founded in 1994 and is unique in guaranteeing our clients that their trials will be delivered on time and within the contract price (our End-to-End guarantee).
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
